Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran

Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran Publisher Pubmed

Nazemipour M¹ ; Shakiba M² ; Mansournia MA³

Show Affiliations

1. Psychosocial Health Research Institute, Iran University of Medical Sciences, Tehran, Iran
2. Cardiovascular Diseases Research Center and School of Health, Guilan University of Medical Sciences, Rasht, Iran
3. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Source: The Lancet Infectious Diseases Published:2021

[No abstract available]

Related Docs

Experts (# of related papers)

Style	Citing Format
MLA	Nazemipour M, Shakiba M, Mansournia MA. "Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran." The Lancet Infectious Diseases, vol. 21, no. 5, 2021, pp. 603-604.
APA	Nazemipour M, Shakiba M, Mansournia MA (2021). Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran. The Lancet Infectious Diseases, 21(5), 603-604.
Chicago	Nazemipour M, Shakiba M, Mansournia MA. "Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran." The Lancet Infectious Diseases 21, no. 5 (2021): 603-604.
Harvard	Nazemipour M, Shakiba M, Mansournia MA (2021) 'Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran', The Lancet Infectious Diseases, 21(5), pp. 603-604.
Vancouver	Nazemipour M, Shakiba M, Mansournia MA. Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran. The Lancet Infectious Diseases. 2021;21(5):603-604.
BibTex	@article{ author = {Nazemipour M and Shakiba M and Mansournia MA}, title = {Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran}, journal = {The Lancet Infectious Diseases}, volume = {21}, number = {5}, pages = {603-604}, year = {2021} }
RIS	TY - JOUR AU - Nazemipour M AU - Shakiba M AU - Mansournia MA TI - Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran JO - The Lancet Infectious Diseases VL - 21 IS - 5 SP - 603 EP - 604 PY - 2021 ER -